Fate Therapeutics, Inc. (FATE)

Market Cap	221.46M +60.9%
Revenue (ttm)	6.32M -52.6%
Net Income	-129.91M
EPS	-1.09
Shares Out	116.56M
PE Ratio	n/a
Forward PE	n/a
Dividend	n/a
Ex-Dividend Date	n/a

Volume	1,888,756
Open	1.950
Previous Close	1.910
Day's Range	1.820 - 2.090
52-Week Range	0.910 - 2.880
Beta	2.52
Analysts	Buy
Price Target	5.41 (+184.74%)
Earnings Date	May 13, 2026

About FATE

Fate Therapeutics, Inc., a clinical-stage biopharmaceutical company, develops programmed cellular immunotherapies for cancer and immune disorders in the United States and internationally. The company’s chimeric antigen receptor (CAR)-targeted NK and T-cell product candidates include FT836 which is in preclinical stage for multiple tumor types; and FT522, to treat B-cell Lymphoma and autoimmunity. Its CAR T-cell programs include FT819 to treat systemic lupus erythematosus, FT839, to treat complex autoimmune diseases; and FT825 to treat solid tum...

• Industry: Biotechnology
• Sector: Healthcare
• IPO Date: Oct 1, 2013
• Employees: 161
• Stock Exchange: NASDAQ
• Ticker Symbol: FATE
• Website: https://www.fatetherapeutics.com

Financial Performance

In 2025, Fate Therapeutics's revenue was $6.65 million, a decrease of -51.24% compared to the previous year's $13.63 million. Losses were -$136.32 million, -26.82% less than in 2024.

Analyst Summary

According to 12 analysts, the average rating for FATE stock is "Buy." The 12-month stock price target is $5.41, which is an increase of 184.74% from the latest price.

Price Target

$5.41

(184.74% upside)

Analyst Consensus: Buy